Cargando…

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers

The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and are frequently associated with tumor cell survival and d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Rong, De Beule, Nathan, Maes, Anke, De Bruyne, Elke, Menu, Eline, Vanderkerken, Karin, Maes, Ken, Breckpot, Karine, De Veirman, Kim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592826/ https://www.ncbi.nlm.nih.gov/pubmed/36304465 http://dx.doi.org/10.3389/fimmu.2022.1016059

Ejemplares similares

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells
por: Wang, Jinheng, et al.
Publicado: (2015)

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
por: Yan, Siyang, et al.
Publicado: (2019)

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
por: De Beck, Lien, et al.
Publicado: (2018)

Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
por: De Veirman, Kim, et al.
Publicado: (2014)

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
por: Fan, Rong, et al.
Publicado: (2023)

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma
por: Vlummens, Philip, et al.
Publicado: (2019)

The therapeutic potential of cell cycle targeting in multiple myeloma
por: Maes, Anke, et al.
Publicado: (2017)

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
por: De Smedt, Eva, et al.
Publicado: (2018)

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
por: Muylaert, Catharina, et al.
Publicado: (2022)

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
por: Oudaert, Inge, et al.
Publicado: (2022)

The genetic landscape of 5T models for multiple myeloma
por: Maes, Ken, et al.
Publicado: (2018)

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma
por: Maes, Anke, et al.
Publicado: (2019)

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
por: De Veirman, Kim, et al.
Publicado: (2015)

Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells
por: De Beule, Nathan, et al.
Publicado: (2017)

Correction: Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells
por: De Beule, Nathan, et al.
Publicado: (2018)

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
por: Vlummens, Philip, et al.
Publicado: (2022)

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
por: Verheye, Emma, et al.
Publicado: (2022)

Novel strategies to target the ubiquitin proteasome system in multiple myeloma
por: Lub, Susanne, et al.
Publicado: (2015)

Metabolic Features of Multiple Myeloma
por: El Arfani, Chaima, et al.
Publicado: (2018)

Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis
por: Oudaert, Inge, et al.
Publicado: (2022)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells
por: Lub, Susanne, et al.
Publicado: (2015)

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
por: Faict, Sylvia, et al.
Publicado: (2018)

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma
por: Wang, Jinheng, et al.
Publicado: (2016)

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma
por: Maes, Anke, et al.
Publicado: (2019)

PB1973: INHIBITION OF LACTATE EXPORTERS INDUCES DIRECT ANTI-TUMOR EFFECTS AND COUNTERS IMMUNE SUPPRESSION IN MULTIPLE MYELOMA
por: Van der Vreken, A., et al.
Publicado: (2022)

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

P860: THE DE NOVO DNA METHYLTRANSFERASE DNMT3B PLAYS AN IMPORTANT ROLE IN MM CELL GROWTH, CLONOGENICITY AND DRUG RESPONSE
por: Muylaert, C., et al.
Publicado: (2022)

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
por: Faict, Sylvia, et al.
Publicado: (2019)

Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy
por: Dufait, Inès, et al.
Publicado: (2016)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
por: Hu, Jinsong, et al.
Publicado: (2012)

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
por: Bieghs, Liesbeth, et al.
Publicado: (2016)

Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2014)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
por: Bieghs, Liesbeth, et al.
Publicado: (2010)

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
por: Emde-Rajaratnam, Martina, et al.
Publicado: (2023)

Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential
por: Maes, Ken, et al.
Publicado: (2021)

Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model
por: Nur, Haneen, et al.
Publicado: (2013)

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
por: Bieghs, Liesbeth, et al.
Publicado: (2014)

Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s245cefafmatn5eiun7dr4jqtc